Literature DB >> 3944460

Induction of protection against Brugia malayi infection in jirds by microfilarial antigens.

J W Kazura, H Cicirello, J W McCall.   

Abstract

The development of immunologic methods to reduce transmission of human lymphatic filariasis depends on measures that will enhance the host's ability to eliminate infective larvae, adult worms, or blood-borne microfilariae (mf). The present study was designed to assess the capacity of a crude extract of Brugia malayi mf to decrease the level of microfilaremia and adult worm burden in jirds inoculated with infective larvae, and to identify the filarial antigens that elicit antibody responses in these animals. Thirty weeks after subcutaneous inoculation with 75 infective larvae, 100% of control jirds were patent (i.e., had microfilaremia) compared with 60% of the group immunized with 10 micrograms of crude microfilarial extract (p less than 0.05). In addition, microfilaremia was lower in patent immunized animals compared with controls (p less than 0.05). The mean total number of adult female B. malayi per jird recovered at necropsy in control animals was 16.0 vs 7.0 in immunized jirds (p less than 0.05). Serum of immunized jirds contained anti-mf antibodies with an end titer of 1:8000, a value similar to that of animals with chronic B. malayi infection. Microfilarial antigens of Mr approximately 150,000, 75,000, 42,000, and 25,000 were identified in immunoblotting studies by reactivity with antibodies in sera of immunized jirds. Antibodies induced by immunization with microfilarial extract were not specific for this stage of the parasite life cycle, as jird anti-mf antibodies reacted with a Mr approximately 150,000 and several Mr 50,000 to 110,000 antigens derived from immature and mature adult parasites of both sexes. These data indicate that immunization of jirds with a water soluble microfilarial extract enhances the host's ability to eliminate adult worms and blood-borne mf. The filarial antigens that induce antibodies in immunized jirds have been identified.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3944460

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Molecular parasitology: progress towards the development of vaccines for malaria, filariasis, and schistosomiasis.

Authors:  S J Cryz
Journal:  Experientia       Date:  1991-02-15

Review 2.  A comprehensive, model-based review of vaccine and repeat infection trials for filariasis.

Authors:  C Paul Morris; Holly Evans; Sasha E Larsen; Edward Mitre
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

3.  Cloning and characterization of a potentially protective antigen in lymphatic filariasis.

Authors:  T W Nilsen; P A Maroney; R G Goodwin; K G Perrine; J A Denker; J Nanduri; J W Kazura
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

4.  Differential regulation of in vitro humoral and cellular immune responsiveness in Brugia pahangi-infected jirds.

Authors:  R C Prier; P J Lammie
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

5.  Lymphatic filariasis: detection of circulating and urinary antigen and differences in antibody isotypes complexed with circulating antigen between symptomatic and asymptomatic subjects.

Authors:  C Lutsch; J Y Cesbron; D Henry; J P Dessaint; K Wandji; M Ismail; A Capron
Journal:  Clin Exp Immunol       Date:  1988-02       Impact factor: 4.330

6.  Induction of murine T-helper-cell responses to the filarial nematode Brugia malayi.

Authors:  E Pearlman; F E Hazlett; W H Boom; J W Kazura
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

7.  Protective immunity in bancroftian filariasis. Selective recognition of a 43-kD larval stage antigen by infection-free individuals in an endemic area.

Authors:  D O Freedman; T B Nutman; E A Ottesen
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

Review 8.  Clinical and laboratory aspects of filariasis.

Authors:  J Nanduri; J W Kazura
Journal:  Clin Microbiol Rev       Date:  1989-01       Impact factor: 26.132

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.